INTRODUCTION
Vaccination of children to prevent infectious disease represents one of the greatest contributions to pediatric health, but is dependent on competent immune system function. Distinct adaptive immune responses occur among very preterm infants as compared with more mature neonates, infants and children. 1 Antibody levels to routine infant vaccines are sometimes lower among very low birth weight (401 to 1500 g, VLBW) infants. 2 The developing neonatal adaptive immune system has a very limited capacity to respond to non-protein antigens (for example, bacterial polysaccharide capsules) until nearly 2 years of age. 3 Protein-conjugated vaccinations (for example, heptavalent pneumococcal conjugate vaccine (PCV7)) capitalize on the largely intact T-cell-dependent B-cell antibody response to protein to promote production of protective immunoglobulins against polysaccharide antigens such as the capsule of Pneumococcus (Streptococcus pneumoniae). D'Angio et al. 4 showed when compared with larger premature infants, infants weighing p1000 g at birth have similar antibody responses to most, but not all, PCV7 vaccine serotypes.
Serious infection or sepsis in children and adults can result in significant short-and long-term quantitative and qualitative alterations in adaptive immune function that alter the host's capacity to respond to infectious challenge. Specifically, sepsis results in a significant loss of dendritic cells (professional antigen presentation cells), T cells and B cells. In addition to cellular losses, long-term functional alterations occur in T cells that may be present weeks to months after sepsis recovery. 9 Epigenetic immune system changes that occur following sepsis are the subject of intense research and have recently been associated with specific histone modifications (methylation, phosphorylation, ubiquitination and sumoylation among others) of critical deoxyribonucleic acid promoter regions. 10 It is unknown how or if sepsis affects the subsequent function of the preterm infant's developing adaptive immune system including vaccine responses. Sepsis is a clinical diagnosis that at present lacks accepted definitive criteria in preterm neonates. 11 However, the high frequency of blood stream infection (BSI; as high as 60%) during hospitalization in the very preterm population [12] [13] [14] [15] makes this clinically relevant. The study of whether BSI modifies subsequent vaccine responses has not been previously performed in pediatrics, specifically because we rarely have the opportunity of obtaining blood prospectively at sequential intervals following vaccination. In this follow-up study of the 1 PCV7 vaccination trial by D'Angio et al. 4 , we identified and characterized the incidence of BSI in a cohort of VLBW infants who received PCV7 vaccine and determined whether BSI was associated with an altered vaccine response.
METHODS Patients
We performed a retrospective cohort study of patients and data prospectively collected for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) study entitled 'heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants' and the NRN Generic Database with respect to the occurrence of BSI during the infant's hospitalization. Infants studied were premature (o32 weeks completed gestation), had BW 401 to 1500 g (VLBW), and were born between June 2004 and October 2006 and cared for in one of nine participating centers in the NICHD NRN. 4 The study was reviewed and approved by each center's Institutional Review Board and monitored by the NICHD Data and Safety Monitoring Committee.
Serology
Infants received PCV7 vaccination at 2, 4 and 6 months after birth and had blood drawn 4 to 6 weeks after the third dose. 4 As described in detail in the primary study, subjects had three doses of PCV7 administered by their clinical providers beginning before 3 months of age and spaced about 2 months apart, either in the neonatal intensive care unit or as outpatients, according to the providers' usual practices and Centers for Disease Control and Prevention and American Academy of Pediatrics recommendations. 4 The amounts of anti-capsular polysaccharide antibody were determined for each of the seven vaccine components (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) by a third-generation enzyme-linked immunosorbent assay. 4 The lower detection limit of the assay was 0.01 to 0.03 mg ml À 1 . Percentages of infants who reached designated cutoff antibody titers of X0.35 mg ml À 1 were compared between infants with and without a history of BSI. This serum antibody cutoff value was chosen for analysis in the primary manuscript based on recommendations from the World Health Organization. 16 Opsonophagocytosis titers (OTs) against the primary serotypes (4, 6B, 14 and 23F) were defined as the serum dilution that killed 50% of the target bacteria in the presence of effector immune cells. 4 Definition of BSI BSI was defined by growth of bacteria or fungi on a blood culture obtained p72 h of birth (early-onset BSI) or 472 h (late-onset BSI) plus antimicrobial treatment (X5 days).
14 Blood cultures were performed based on clinical concern for infection and were not related to the primary study. Positive blood cultures with different pathogens (genus and species) taken X5 days apart or same pathogen X14 days apart were considered indicative of different episodes. Cultures that grew coagulase-negative Staphylococcus (CoNS) were included only if the infant received antimicrobial treatment for X5 days. Blood cultures positive with Corynebacterium, Propionibacterium or Micrococcus were considered contaminated. Infants with cultures positive with any three organisms or two organisms that included a contaminant listed above were deemed uninfected and were included in the 'no BSI' group. In the primary paper, 88 infants had culture-proven systemic infection before discharge. Among those 88, 2 had meningitis only (no BSI) and were excluded from our analysis. An additional three were considered contaminants by our definition of BSI (all had cultures positive with three organisms or two organisms that included a contaminant). Finally, one infant was recorded as having BSI but had a missing organism code. Thus, we excluded these six infants to focus on BSI with known etiology. BSI episodes were classified based on the pathogen recovered (gram positive, gram negative or fungus). If more than one pathogen was recovered with a valid episode of BSI, each organism was counted. Regarding the effect of specific pathogen class on PCV7 and OT, we only considered the causative organism for the first episode of BSI for infants with more than one episode.
Primary outcome
The primary outcome was the percentage of VLBW infants with or without a history of BSI who achieved antibody titers X0.35 mg ml À 1 to PCV7 serotypes.
Statistical considerations
Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA). Weight-for-corrected-age Z score at the time of the blood draw was estimated using the 2000 Centers for Disease Control and Prevention growth chart (http://www.cdc.gov/growthcharts). Student's t-test was used to compare the mean BW, gestational age, 5-min Apgar score between infants with and without BSI and w 2 tests were used to compare the frequency of neonatal comorbidities defined in a previous NRN study. 14 The percentage of infants that achieved cutoff serum antibody titer (X0.35 mg ml À 1 ) following completion of the PCV7 vaccination series, and OT 41:8 (against serotypes 4, 14 and 23F) were compared between groups (with or without BSI) using w 2 test. Logistic regression models for serum antibody cutoff, and OT (serotype 6B) were constructed with adjustment for BW group (p1000 or 41000 g) and other confounding factors identified in the primary study (sex, race, postnatal glucocorticoid treatment, Z-score of weight for corrected age at blood draw and age at first vaccination).
RESULTS

Patient demographics
Out of 369 infants enrolled in the primary study, 244 completed their three-dose PCV7 series by 8 months of age and had antibody Figure 1) . Of these 244 eligible infants, 82 experienced BSI by our definition (Table 1) . Forty-eight percent (118/244) were p1000 g at birth. Among the 118 infants of p1000 g BW, mean BW was 826±127 g without BSI vs 702 ± 159 g with BSI and mean gestational age 27 ± 1.6 vs 26 ± 1.6 weeks.
BSI and associated pathogens As seven episodes of BSI were associated with growth of two valid pathogens, the number of episodes (n ¼ 122) does not equal the number of recovered pathogens (n ¼ 129, Table 2 ). Gram-positive organisms were the predominant pathogens associated with BSI episodes. Coagulase-negative Staphylococcus was the most commonly isolated organism. Owing to very low sample size, fungal infections (n ¼ 9) were not analyzed.
Timing of BSI episodes and first PCV7 vaccination In all, 122 episodes of BSI occurred in 82/244 (34%) infants. The majority (77/82) of infants who developed BSI were diagnosed only with late-onset BSI. Thirty-three percent (27/82) of infants with BSI experienced two or more episodes of BSI during their hospitalization. The median day of life for the first documented episode of BSI was 16 (25th to 75th percentile: 11 to 27 days) and 76% (62/82) of the first BSI episode for patients in our cohort occurred o28 days after birth. We specifically examined the timing of BSI episodes and first PCV7 vaccination in our cohort of 244 infants to determine the degree of overlap of these two events (Supplementary Figure 2) . We first chose the day of life where o10% of infants had received their first dose of PCV7 (57 days). We then determined the number of infants that had experienced at least one episode of BSI (79/82, 96%) as well as the percent of all episodes of BSI that had occurred by that time point (102/122, 84%). Thus, very little overlap occurred between the timing of BSI and the timing of the first vaccination.
BSI and the percentage of infants that reached protective PCV7 antibody cutoff Overall, there was a difference between groups (BSI vs no BSI) in achieving the protective cutoff of X0.35 mg ml À 1 for serotypes 4, 6B and 23F. After adjustment for other covariates the difference was no longer significant (Table 3) . When the analysis was restricted to infants with BWp1000 g (n ¼ 118) or to only infants o28 weeks no changes in odds of serum antibody X0.35 mg ml À 1 occurred.
Association of BSI and PCV7 OTs
In unadjusted analyses, infants with BSI had a reduced percentage of OT 41:8 against serotype 6B compared with infants without BSI (83% vs 97%, Po0.01). The association of BSI with reduced 6B OT persisted when we restricted the analyses to BSI caused by only gram-positive pathogens, only gram-positive pathogens with 16 in preterm VLBW infants when measured 4 to 6 weeks after vaccination at 2, 4 and 6 months of life. However, BSI was associated with altered responses including a reduced OT 41:8 against serotype 6B in this cohort of preterm neonates. To our knowledge, this is the first study to report the association of BSI and the subsequent vaccine response in the VLBW infant.
As the majority of vaccines are given in early life, evaluations of the effect of pediatric and adult sepsis on subsequent vaccine responses are scarce. We are not aware of any previous study in neonates that has examined the impact of BSI on subsequent adaptive immune function in general or specifically through the production of antibodies following vaccination. Immunologic functional studies of adaptive immune responses following sepsis are available from experiments performed in adult animals but these may not accurately reflect the situation in preterm infants. 9, 10, 17 However, in those studies, altered adaptive immune cellular responses (altered T helper cell function) persisted for months in fully recovered, previously septic adult mice. Specifically, Scumpia et al. 17 showed T-cell-dependent B-cell responses (immunoglobulin M and immunoglobulin G2a) are reduced after polymicrobial peritoneal sepsis (induced by cecal ligation and puncture) and Delano et al. 9 demonstrated these deficiencies persist for up to 3 months. These changes represent a shift from a T-helper 1 to a T-helper 2 immunophenotype that is associated with an altered immunoglobulin production profile particularly for immunoglobulin G2a. Neonates manifest a T-helper 2 phenotype at baseline and produce less IgG2 (ref. 18) that is important for protection against encapsulated organisms such as pneumococcus. 19 Our findings are potentially relevant for several reasons. First, vaccine response (either achievement of protective cutoff concentration and/or adequate OT) for serotypes 23F and 6B were low in the primary study, and this finding has been recently confirmed in another cohort of preterm infants. 20 In addition, these serotypes are associated with invasive disease in infants and 6B is the most common serotype for breakthrough infection following vaccination. 21, 22 Second, the frequency of BSI in the preterm infant can be as high as 60% in the most immature infants.
14 Our findings that BSI alters the host response to PCV7 vaccination may also be true for other vaccine responses and may partially explain why preterm infants may exhibit reduced vaccine responses. 2 Of note is the relationship between attaining the prescribed 'protective' cutoff of antibody concentrations and effective antibody-mediated opsonophagocytosis of the live pathogen. Effective opsonophagocytosis was determined using He-La cells in the presence of additional rabbit serum as a source for complement in the primary study. Although this assay was used to assess all samples obtained from preterm infants, the in vivo function of preterm phagocytes and serum level of complement components may not mirror the effectiveness demonstrated using this method of ex vivo immune function modeling. 23 
LIMITATIONS
One specific weakness of this retrospective study is the nonrandom distribution of patients. It is possible that infants develop BSI as a result of altered immune function that may also be associated with reduced vaccine responses. However, the role of the adaptive immune system in the risk of developing BSI and the host response to sepsis is inadequately characterized in neonates. Furthermore, unlike in adults and children, where a large part of the post sepsis-associated immune alterations occur in the adaptive immune system, data are lacking that describe a similar dependence of the preterm infant on the adaptive immune system for protection against infection (and point more to the critical importance of innate immune system function) 24 . Nasopharyngeal colonization with pneumococcus may reduce the immune response to vaccination. 25 However, PCV7 vaccine serotypes were not identified in a recent examination of nasopharyngeal colonization of infants in this cohort. 26 In our study, BSI was detected and treated in infants evaluated for sepsis based on clinical suspicion of infection. Specific clinical parameters to discriminate between cases of sepsis and septic shock vs BSI are not well established in preterm infants. 11 Thus, it is possible that further alterations in the PCV7 immune response were associated with neonatal sepsis or septic shock that we were not able to detect. Finally, multiple subgroup analyses can potentially overstate the significance of findings. We did not adjust the P-value for multiple comparisons and thus the significance of the estimated effects from multiple subgroup analysis could be inflated. However, we intended to show if there was a CONCLUSIONS VLBW infants with a history of BSI achieve protective antibody cutoffs after PCV7 vaccination. However, BSI was associated with an altered vaccine response for selected serotypes often associated with infection after vaccination; an association not explained by gestational age or BW. This finding may represent the presence of sepsis-induced immune system modifications with clinical significance in this fragile population. managed and analyzed the data for this study. One behalf of the NRN, Dr A Das (DCC Principal Investigator) and Dr L Li (DCC Statistician) had full access to all of the data in the study, and with the NRN Center Principal Investigators, take responsibility for the integrity of the data and accuracy of the data analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in this study.
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